C1 inhibitor use reduces attacks in hereditary angioedema

March 23, 2017

(HealthDay)—Prophylactic use of the subcutaneous C1 inhibitor CSL830 is associated with a reduction in the frequency of acute attacks in patients with hereditary angioedema, according to a study published in the March 23 issue of the New England Journal of Medicine.

Hilary Longhurst, M.D., from the Barts Health NHS Trust in London, and colleagues conducted a randomized phase 3 trial to examine the efficacy and safety of self-administered subcutaneous CSL830. Patients with type I or type II hereditary angioedema who had four or more attacks in a two-month period were randomized to one of four treatment sequences involving two 16-week treatment periods with 40 or 60 IU of CSL830/kg body weight twice weekly, followed by placebo or vice versa. Seventy-nine patients completed the trial.

The researchers found that, compared with placebo, both doses of CSL830 reduced the rate of attacks of hereditary angioedema (mean difference with 40 and 60 IU, −2.42 and −3.51 attacks per month, repectively). The response rates were 76 and 90 percent in the 40- and 60-IU groups, respectively. The need for rescue medication was reduced from 5.55 to 1.13 uses per month in the placebo and 40-IU groups, respectively, and from 3.89 to 0.32 uses per month in the and 60-IU groups, respectively.

"In with hereditary angioedema, the prophylactic use of a subcutaneous C1 inhibitor twice weekly significantly reduced the frequency of acute attacks," the authors write.

The study was funded by CSL Behring, the manufacturer of CSL830.

Explore further: Clinical trial supports use of novel preventive therapy for dangerous swelling disorder

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Clinical trial supports use of novel preventive therapy for dangerous swelling disorder

February 27, 2017
clinical trial for a new drug to prevent attacks of hereditary angioedema (HAE) - a rare disorder characterized by recurrent swelling of tissues in the face, hands, gastrointestinal tract and airway - has had promising results. ...

Omalizumab effective for chronic spontaneous urticaria

March 31, 2016
(HealthDay)—Omalizumab is effective in patients with moderate-to-severe chronic spontaneous urticaria (CSU) symptoms and angioedema unresponsive to high doses of antihistamine treatment, according to a study published online ...

In rare disorder, novel agent stops swelling before it starts

February 22, 2017
An early-stage clinical trial has found that, compared to a placebo, a novel medication significantly reduces potentially life-threatening episodes of swelling of the airway as well as the hands, feet, and abdomen of patients ...

A better way to treat ACE inhibitor angioedema in the ED

May 14, 2014
Investigators at the University of Cincinnati have found a safe and effective treatment for life-threatening angioedema attacks in the emergency department.

rhC1INH cuts attack frequency in hereditary angioedema

November 9, 2012
(HealthDay)—For patients with hereditary angioedema (HAE), weekly administration of recombinant C1INH (rhC1INH) is well tolerated and is associated with a reduction in attack frequency, according to a study published online ...

Secukinumab cuts symptoms of ankylosing spondylitis

December 24, 2015
(HealthDay)—For patients with active ankylosing spondylitis, secukinumab is associated with reductions in symptoms at week 16, according to a study published in the Dec. 24 issue of the New England Journal of Medicine.

Recommended for you

Breakthrough in designing a better Salmonella vaccine

September 24, 2018
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing ...

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

New findings on the muscle disease Laing early-onset distal myopathy

September 24, 2018
New avenues are now being opened toward treatment of Laing distal myopathy, a rare disorder that causes atrophy of the muscles in the feet, hands and elsewhere. In a study published in the journal PNAS, researchers have identified ...

Insulin shows great potential against chronic colitis

September 24, 2018
Diabetes is not the only disease on which insulin has an effect, it appears. In a new study using tests on mice, researchers from the University of Copenhagen, among others, have discovered a new method for treating chronic ...

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.